Corporate Report

The report covers ONO PHARMACEUTICAL's 2014 fiscal year and combines consolidated financial results with CSR reporting. It highlights OPDIVO's approvals and launch in Japan and the U.S.A., alongside expansion of overseas subsidiaries in South Korea and Taiwan. CSR priorities include human resources and human rights, the environment, fair operating practices, and society, supported by a CSR Committee. The report also includes limited independent assurance of energy-derived CO2 emissions from domestic business locations.